Express Pharma

Agilent – Advance Your Peptide Product Commercialization

0 156

Synthetic peptide therapeutics, encompassing a range of artificially created peptides, have emerged as a significant area of pharmaceutical development. Their specificity and safety profile make them a promising solution for addressing unmet medical challenges. Yet, alongside innovative modifications and intricate formulations emerge fresh hurdles. As this domain burgeons, sophisticated manufacturing, analytical tools, and refined data analysis become imperative for evaluating these peptides effectively.

 

Watch these thought-provoking two-part webinar series on the entire value chain of therapeutic peptides and Learn about:

  • Peptide manufacturing specifications
  • Recommendations and general chapters from USP in ensuring quality
  • Streamlined workflows for producing high-quality API
  • End-to-end analytical to preparative workflow for synthetic peptides
  • How USP standards ensures the quality of DS and DP
  • LC/MS based characterization workflow
  • Case Study: GLP-1 peptides on impurity profiling
  • Selection of analytical techniques and samples
  • Guidelines for assessing analytical similarities
  • And much more

    This is co-hosted by Express Pharma and Agilent

    By submitting this form, you are confirming you are an adult 18 years or older and agree to Express Pharma contacting you with marketing-related emails or by telephone. You may unsubscribe from receiving such communications from Express Pharma at any time. Express Pharma web sites and communications are subject to our Privacy Notice and Terms of Use.

    Yes, I would like to receive email updates about Agilent products, services and events.
    For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy


    Leave A Reply

    Your email address will not be published.